.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EB11_Aumolertinib.Aumolertinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EB11_Aumolertinib.Aumolertinib| name: | Aumolertinib | |
| ATC code: | L01EB11 | route: | oral |
| compartments: | 2 | |
| dosage: | 110 | mg |
| volume of distribution: | 306 | L |
| clearance: | 19.2 | L/h |
| other parameters in model implementation | ||
Aumolertinib is a third-generation, oral, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). It is approved in China for the treatment of patients with advanced or metastatic NSCLC harboring EGFR mutations.
Pharmacokinetic parameters in adult patients with advanced NSCLC following oral administration. Population PK analyses and clinical studies support the following estimates.